1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW

3. MARKET DYNAMICS
3.1. MARKET DEFINITION
3.2. KEY DRIVERS
3.2.1. MODERN DIETARY HABITS TAKING TOLL ON THE HEALTH
3.2.2. IBS CAN BE A HERITABILITY ISSUE
3.2.3. AVAILABILITY OF EFFECTIVE DRUGS IN THE MARKET
3.3. KEY RESTRAINTS
3.3.1. STRICT FDA REGULATIONS
3.3.2. UNAWARENESS AND IGNORANCE AMONG PEOPLE

4. KEY ANALYTICS
4.1. KEY INVESTMENT INSIGHTS
4.2. PORTER’S FIVE FORCE ANALYSIS
4.2.1. BUYER POWER
4.2.2. SUPPLIER POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. OPPORTUNITY MATRIX
4.4. VENDOR LANDSCAPE
4.5. REGULATORY FRAMEWORK

5. MARKET BY PRESCRIPTION TYPE
5.1. PRESCRIBED
5.1.1. BRANDED
5.1.2. GENERIC
5.2. OVER THE COUNTER

6. MARKET BY DRUG TYPE
6.1. LUBIPROSTONE
6.2. LINACLOTIDE
6.3. STIMULANT LAXATIVES
6.3.1. BISACODYL
6.3.2. SENNA
6.4. OSMOTIC LAXATIVES
6.4.1. LACTULOSE
6.4.2. POLYETHYLENE GLYCOL
6.5. OTHER DRUG TYPES

7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. UNITED STATES
7.1.2. CANADA

8. COMPANY PROFILES
8.1. CATALENT PHARMACEUTICALS SOLUTIONS
8.2. ABBOTT LABORATORIES
8.3. NOVARTIS PHARMA AG
8.4. ASTELLAS PHARMACEUTICALS
8.5. ARDELYX, INC.
8.6. SYNTHETIC BIOLOGICS, INC.
8.7. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
8.8. BAMA-GEVE, SLU
8.9. FERRING BV
8.10. IRONWOOD PHARMACEUTICALS, INC.
8.11. SALIX PHARMACEUTICALS LTD.
8.12. NORGINE B.V.
8.13. PROMETHEUS LABORATORIES, INC.
8.14. ALBIREO PHARMA, INC.
8.15. YUHAN CORP.
8.16. ASTRAZENECA PLC
8.17. THE MENARINI GROUP
8.18. ONO PHARMACEUTICAL CO. LTD.
8.19. ACTAVIS NORDIC A/S

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT – IBS-C DRUG
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: NORTH AMERICA IBS-C DRUG MARKET, BY PRESCRIPTION TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 4: NORTH AMERICA IBS-C DRUG MARKET, BY PRESCRIPTION TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 5: NORTH AMERICA IBS-C DRUG MARKET, BY PRESCRIBED, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 6: NORTH AMERICA IBS-C DRUG MARKET, BY PRESCRIBED, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 7: PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)
TABLE 8: NORTH AMERICA IBS-C DRUG MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 9: NORTH AMERICA IBS-C DRUG MARKET, BY DRUG TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 10: PRODUCT PROFILE (LUBIPROSTONE)
TABLE 11: PRODUCT PROFILE (LINACLOTIDE)
TABLE 12: NORTH AMERICA IBS-C DRUG MARKET, BY STIMULANT LAXATIVES, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 13: NORTH AMERICA IBS-C DRUG MARKET, BY STIMULANT LAXATIVES, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 14: PRODUCT PROFILE (BISACODYL)
TABLE 15: PRODUCT PROFILE (SENNA)
TABLE 16: NORTH AMERICA IBS-C DRUG MARKET, BY OSMOTIC LAXATIVES, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 17: NORTH AMERICA IBS-C DRUG MARKET, BY OSMOTIC LAXATIVES, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 18: PRODUCT PROFILE (LACTULOSE)
TABLE 19: PRODUCT PROFILE (POLYETHYLENE GLYCOL)
TABLE 20: PRODUCT PROFILE (PSYLLIUM)
TABLE 21: NORTH AMERICA IBS-C DRUG MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 22: NORTH AMERICA IBS-C DRUG MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

LIST OF FIGURES
FIGURE 1: DRUGS PULLED OFF FROM THE MARKET
FIGURE 2: KEY INVESTMENT INSIGHTS
FIGURE 3: PORTER’S FIVE FORCE ANALYSIS
FIGURE 4: OPPORTUNITY MATRIX
FIGURE 5: VENDOR LANDSCAPE
FIGURE 6: NORTH AMERICA IBS-C DRUG MARKET, GROWTH POTENTIAL, BY PRESCRIPTION TYPE, IN 2019
FIGURE 7: NORTH AMERICA IBS-C DRUG MARKET, PRESCRIBED, 2020-2028 (IN $ MILLION)
FIGURE 8: NORTH AMERICA IBS-C DRUG MARKET, BRANDED, 2020-2028 (IN $ MILLION)
FIGURE 9: NORTH AMERICA IBS-C DRUG MARKET, GENERIC, 2020-2028 (IN $ MILLION)
FIGURE 10: NORTH AMERICA IBS-C DRUG MARKET, OVER THE COUNTER, 2020-2028 (IN $ MILLION)
FIGURE 11: NORTH AMERICA IBS-C DRUG MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2019
FIGURE 12: NORTH AMERICA IBS-C DRUG MARKET, LUBIPROSTONE, 2020-2028 (IN $ MILLION)
FIGURE 13: NORTH AMERICA IBS-C DRUG MARKET, LINACLOTIDE, 2020-2028 (IN $ MILLION)
FIGURE 14: NORTH AMERICA IBS-C DRUG MARKET, STIMULANT LAXATIVES, 2020-2028 (IN $ MILLION)
FIGURE 15: NORTH AMERICA IBS-C DRUG MARKET, BISACODYL, 2020-2028 (IN $ MILLION)
FIGURE 16: NORTH AMERICA IBS-C DRUG MARKET, SENNA, 2020-2028 (IN $ MILLION)
FIGURE 17: NORTH AMERICA IBS-C DRUG MARKET, OSMOTIC LAXATIVES, 2020-2028 (IN $ MILLION)
FIGURE 18: NORTH AMERICA IBS-C DRUG MARKET, BISACODYL, 2020-2028 (IN $ MILLION)
FIGURE 19: NORTH AMERICA IBS-C DRUG MARKET, POLYETHYLENE GLYCOL, 2020-2028 (IN $ MILLION)
FIGURE 20: NORTH AMERICA IBS-C DRUG MARKET, OTHER DRUG TYPES, 2020 -2028 (IN $ MILLION)
FIGURE 21: NORTH AMERICA IBS-C DRUG MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
FIGURE 22: UNITED STATES IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 23: CANADA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)